Lupus nephritis diagnostic study of choice: Difference between revisions
Created page with "__NOTOC__ {{Lupus nephritis}} {{CMG}}; {{AE}} == Overview == * The page name should be '''"[Disease name] diagnostic study of choice"''', with only the first letter of the tit..." |
|||
(5 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Lupus nephritis}} | {{Lupus nephritis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{OK}} | ||
== Overview == | ==Overview== | ||
In SLE, nephritis we suspect renal involvment by an abnormal urinalysis and/or increased serum creatinine. Histopathologic findings on renal biopsy confirm the diagnosis. | |||
== Diagnostic | ==Diagnostic criteria== | ||
In 2012, Systemic Lupus International Collaboration Criteria (SLICC) developed a new criteria for SLE diagnosis. SLICC criteria for the classification of [[systemic lupus erythematosus]] was developed based on the old ACR criteria for the classification of [[systemic lupus erythematosus]] to address a more sensitive diagnostic criteria and also to cover weaknesses of the previous ACR criteria.<ref name="pmid7138600">{{cite journal |vauthors=Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ |title=The 1982 revised criteria for the classification of systemic lupus erythematosus |journal=Arthritis Rheum. |volume=25 |issue=11 |pages=1271–7 |year=1982 |pmid=7138600 |doi= |url=}}</ref><ref name="pmid9324032">{{cite journal |vauthors=Hochberg MC |title=Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus |journal=Arthritis Rheum. |volume=40 |issue=9 |pages=1725 |year=1997 |pmid=9324032 |doi=10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y |url=}}</ref> | |||
===== | Based on SLICC criteria, diagnosis of SLE is defined as:<ref name="pmid22553077">{{cite journal |vauthors=Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G, Magder LS |title=Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus |journal=Arthritis Rheum. |volume=64 |issue=8 |pages=2677–86 |year=2012 |pmid=22553077 |pmc=3409311 |doi=10.1002/art.34473 |url=}}</ref> | ||
* Meeting at least 4 of 17 criteria, including at least 1 of the 11 clinical criteria and one of the six [[Immunological|immunologic]] criteria | |||
'''OR''' | |||
* Biopsy-proven [[nephritis]] compatible with [[SLE]] in the presence of [[Antinuclear antibodies|antinuclear antibodies (ANA)]] or [[Double stranded DNA antibody|anti-double-stranded DNA]] (dsDNA) [[antibodies]] | |||
'''A criterion is considered positive if one or more of the observations listed in the definition for the criterion are present in the patient. A criterion should only be counted once, regardless of the number of observations in the definition that the patient presents with.''' | |||
{| class="wikitable" | |||
! align="center" style="background: #4479BA; color: #FFFFFF; " |Category | |||
! align="center" style="background: #4479BA; color: #FFFFFF; " |Criterion | |||
! align="center" style="background: #4479BA; color: #FFFFFF; " |Definition | |||
|- | |||
| rowspan="8" |<small>Clinical</small> | |||
! style="background: #DCDCDC; " | Acute cutaneous lupus | |||
| | |||
* Lupus [[malar rash]] | |||
** Fixed [[erythema]], flat or raised, over the [[malar]] eminences, tending to spare the [[nasolabial folds]] | |||
* [[Bullous]] lupus | |||
* [[Toxic epidermal necrolysis]] variant of SLE | |||
* [[Maculopapular rash|Maculopapular]] lupus [[rash]] | |||
* [[Photosensitive]] lupus [[rash]] (in the absence of [[dermatomyositis]]); | |||
** Skin [[rash]] as a result of unusual reaction to sunlight, by patient history or physician observation | |||
= | * Subacute cutaneous lupus | ||
* [ | ** Nonindurated psoriaform and/or annular polycyclic [[lesions]] that resolve without [[scarring]], although occasionally with [[Postinflammatory hypopigmentation|postinflammatory dyspigmentation]] or [[Telangiectasia|telangiectasias]] | ||
* | |- | ||
** | ! style="background: #DCDCDC; " |Chronic cutaneous lupus | ||
** | | | ||
* | * Classic [[Discoid lupus|discoid rash]] | ||
* | ** Localized (above the neck) | ||
* | ** Generalized (above and below the neck) | ||
* [ | ** [[Hypertrophic]] (verrucous) lupus | ||
* | ** Lupus [[panniculitis]] (profundus) | ||
* | ** [[Mucosal]] lupus | ||
* | ** [[Lupus erythematosus]] tumidus | ||
* [ | ** Chilblains lupus OR | ||
* | ** Discoid lupus[[Lichen planus|/lichen planus]] overlap | ||
** | |- | ||
** | ! style="background: #DCDCDC; " |Nonscarring [[alopecia]] | ||
** | | | ||
* Diffuse thinning or hair fragility with visible broken hairs (in the absence of other causes, such as [[alopecia areata]], drugs, [[iron deficiency]], and [[androgenic alopecia]]) | |||
|- | |||
! style="background: #DCDCDC; " |[[Oral ulcer|Oral]] or nasal ulcers | |||
| | |||
* [[Palate]], [[buccal]], [[tongue]], or nasal [[ulcers]] (in the absence of other causes, such as [[vasculitis]], [[Behçet's disease]], [[infection]], [[inflammatory bowel disease]], [[reactive arthritis]], and acidic foods) | |||
|- | |||
! style="background: #DCDCDC; " |[[Arthralgia|Joint disease]] | |||
| | |||
* [[Synovitis]] involving two or more [[joints]], characterized by [[swelling]] or effusion | |||
* [[Tenderness]] in two or more [[joints]] and at least 30 minutes of morning stiffness | |||
|- | |||
! style="background: #DCDCDC; " |[[Serositis]] | |||
| | |||
* Typical [[pleurisy]] for more than one day, [[Pleural effusion|pleural effusions]], or [[pleural]] rub | |||
* Typical pericardial pain (pain with recumbency improved by sitting forward) for more than one day, [[pericardial effusion]], pericardial rub, or [[pericarditis]] by [[electrocardiography]] in the absence of other causes, such as [[infection]], [[uremia]], and [[Dressler's syndrome]] | |||
|- | |||
! style="background: #DCDCDC; " |[[Renal]] | |||
| | |||
* Urine protein-to-[[creatinine]] ratio (or 24-hour urine protein) representing 500 mg protein/24 hours | |||
* [[Red blood cell]] casts | |||
|- | |||
! style="background: #DCDCDC; " |[[Neurological|Neurologic]] | |||
| | |||
* [[Seizure|Seizures]] | |||
* [[Psychosis]] | |||
* [[Mononeuritis multiplex]] (in the absence of other known causes, such as primary [[vasculitis]]) | |||
* [[Myelitis]] | |||
* [[Peripheral neuropathy|Peripheral]] or [[Neuropathy|cranial neuropathy]] (in the absence of other known causes, such as primary [[vasculitis]], [[infection]], and [[diabetes mellitus]]) | |||
* [[Confusion|Acute confusional state]] (in the absence of other causes, including toxic/metabolic, [[uremia]], drugs) | |||
|- | |||
| rowspan="3" |<small>[[Hematologic]]</small> | |||
! style="background: #DCDCDC; " |[[Hemolytic anemia]] | |||
| | |||
* [[Hemoglobin]] less than 12 g/dL in females and 13 g/dL in males | |||
|- | |||
! style="background: #DCDCDC; " |[[Leukopenia]] or [[lymphopenia]] | |||
| | |||
* [[Leukopenia]] (<4000/mm3 at least once) (in the absence of other known causes, such as [[Felty's syndrome]], [[drugs]], and [[portal hypertension]]) | |||
* [[Lymphopenia]] (<1000/mm3 at least once) (in the absence of other known causes, such as [[glucocorticoids]], [[drugs]], and [[infection]]) | |||
|- | |||
! style="background: #DCDCDC; " |[[Thrombocytopenia]] | |||
! style="background: # | | | ||
! style="background: # | * [[Thrombocytopenia]] (<100,000/mm3) at least once in the absence of other known causes, such as [[drugs]], [[portal hypertension]], and [[thrombotic thrombocytopenic purpura]] | ||
! style="background: # | |- | ||
| rowspan="6" |<small>[[Immunological|Immunologic]]</small> | |||
! style="background: #DCDCDC; " |[[ANA]] | |||
| | |||
* [[ANA]] level above laboratory reference range | |||
|- | |||
! style="background: #DCDCDC; " |[[Anti-dsDNA antibody|Anti-dsDNA]] | |||
| | |||
* [[Anti-dsDNA antibody]] level above laboratory reference range (or >twofold the reference range if tested by [[Enzyme linked immunosorbent assay (ELISA)|ELISA]]) | |||
|- | |||
! style="background: #DCDCDC; " |Anit-SM | |||
| | |||
* Presence of [[antibody]] to [[Smith antigen|Sm nuclear antigen]] | |||
|- | |||
! style="background: #DCDCDC; " |[[Antiphospholipid antibody|Antiphospholipid]] | |||
| | |||
* [[Antiphospholipid antibodies|Antiphospholipid antibody]] positivity as determined by any of the following: | |||
** Positive test result for [[lupus anticoagulant]] | |||
** False-positive test result for [[rapid plasma reagin]] | |||
** Medium- or high-titer [[anticardiolipin antibody]] level ([[IgA]], [[IgG]], or [[IgM]]) | |||
** Positive test result for anti-beta 2-glycoprotein I ([[IgA]], [[IgG]], or [[IgM]]) | |||
|- | |- | ||
! style="background: # | ! style="background: #DCDCDC; " |Low [[complement]] | ||
| | | | ||
| | * Low [[C3 glomerular disease|C3]] | ||
* Low [[C4 disease|C4]] | |||
* Low CH50 | |||
|- | |- | ||
! style="background: # | ! style="background: #DCDCDC; " |[[Coombs' Test|Direct Coombs' test]] | ||
| | | | ||
| | * [[Coombs' Test|Direct Coombs' test]] in the absence of [[hemolytic anemia]] | ||
|} | |} | ||
==== | == Renal Involvement == | ||
=== | === Urinanalysis: === | ||
Hematuria and cellular cast<ref name="pmid18046678">{{cite journal |vauthors=Lee LC, Lam KK, Lee CT, Chen JB, Tsai TH, Huang SC |title="Full house" proliferative glomerulonephritis: an unreported presentation of subacute infective endocarditis |journal=J. Nephrol. |volume=20 |issue=6 |pages=745–9 |date=2007 |pmid=18046678 |doi= |url=}}</ref> | |||
Protein excretion and protein to creatinine ratio | |||
Increased anti-DNA titers <ref name="pmid15780090">{{cite journal |vauthors=Haas M, Kaul S, Eustace JA |title=HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases |journal=Kidney Int. |volume=67 |issue=4 |pages=1381–90 |date=April 2005 |pmid=15780090 |doi=10.1111/j.1523-1755.2005.00215.x |url=}}</ref> | |||
Low complement (C3 and C4) levels<ref name="pmid11145039">{{cite journal |vauthors=Ramos-Casals M, Font J, García-Carrasco M, Cervera R, Jiménez S, Trejo O, de la Red G, Sánchez-Tapias JM, Ingelmo M |title=Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus |journal=Arthritis Rheum. |volume=43 |issue=12 |pages=2801–6 |date=December 2000 |pmid=11145039 |doi=10.1002/1529-0131(200012)43:12<2801::AID-ANR21>3.0.CO;2-V |url=}}</ref> | |||
==== Renal Biospy: ==== | |||
Histopathology will guide the treatment.<ref name="pmid11682680">{{cite journal |vauthors=Smet AD, Kuypers D, Evenepoel P, Maes B, Messiaen T, Van Damme B, Vanrenterghem Y |title='Full house' positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt |journal=Nephrol. Dial. Transplant. |volume=16 |issue=11 |pages=2258–62 |date=November 2001 |pmid=11682680 |doi= |url=}}</ref> | |||
* Glomerular deposits: "Full house" immunofluorescence pattern containing IgG, immunoglobulin A (IgA), immunoglobulin M (IgM), C3, and C1q. | |||
* Mesangial, subendothelial, and subepithelial glomerular deposits. | |||
* Tubular basement membrane, the interstitial, and blood vessels extraglomerular immune-type deposits.<ref name="pmid7814619">{{cite journal |vauthors=Rich SA |title=De novo synthesis and secretion of a 36-kD protein by cells that form lupus inclusions in response to alpha-interferon |journal=J. Clin. Invest. |volume=95 |issue=1 |pages=219–26 |date=January 1995 |pmid=7814619 |pmc=295410 |doi=10.1172/JCI117643 |url=}}</ref> | |||
* Glomerular endothelial cells containing tubuloreticular inclusions composed of ribonucleoprotein and membrane, usually stimulated by alpha-interferon. | |||
==References== | ==References== |
Latest revision as of 15:20, 20 July 2018
Lupus nephritis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Lupus nephritis diagnostic study of choice On the Web |
American Roentgen Ray Society Images of Lupus nephritis diagnostic study of choice |
Risk calculators and risk factors for Lupus nephritis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
In SLE, nephritis we suspect renal involvment by an abnormal urinalysis and/or increased serum creatinine. Histopathologic findings on renal biopsy confirm the diagnosis.
Diagnostic criteria
In 2012, Systemic Lupus International Collaboration Criteria (SLICC) developed a new criteria for SLE diagnosis. SLICC criteria for the classification of systemic lupus erythematosus was developed based on the old ACR criteria for the classification of systemic lupus erythematosus to address a more sensitive diagnostic criteria and also to cover weaknesses of the previous ACR criteria.[1][2]
Based on SLICC criteria, diagnosis of SLE is defined as:[3]
- Meeting at least 4 of 17 criteria, including at least 1 of the 11 clinical criteria and one of the six immunologic criteria
OR
- Biopsy-proven nephritis compatible with SLE in the presence of antinuclear antibodies (ANA) or anti-double-stranded DNA (dsDNA) antibodies
A criterion is considered positive if one or more of the observations listed in the definition for the criterion are present in the patient. A criterion should only be counted once, regardless of the number of observations in the definition that the patient presents with.
Category | Criterion | Definition |
---|---|---|
Clinical | Acute cutaneous lupus |
|
Chronic cutaneous lupus |
| |
Nonscarring alopecia |
| |
Oral or nasal ulcers |
| |
Joint disease |
| |
Serositis |
| |
Renal |
| |
Neurologic |
| |
Hematologic | Hemolytic anemia |
|
Leukopenia or lymphopenia |
| |
Thrombocytopenia |
| |
Immunologic | ANA |
|
Anti-dsDNA |
| |
Anit-SM |
| |
Antiphospholipid |
| |
Low complement | ||
Direct Coombs' test |
|
Renal Involvement
Urinanalysis:
Hematuria and cellular cast[4]
Protein excretion and protein to creatinine ratio
Increased anti-DNA titers [5]
Low complement (C3 and C4) levels[6]
Renal Biospy:
Histopathology will guide the treatment.[7]
- Glomerular deposits: "Full house" immunofluorescence pattern containing IgG, immunoglobulin A (IgA), immunoglobulin M (IgM), C3, and C1q.
- Mesangial, subendothelial, and subepithelial glomerular deposits.
- Tubular basement membrane, the interstitial, and blood vessels extraglomerular immune-type deposits.[8]
- Glomerular endothelial cells containing tubuloreticular inclusions composed of ribonucleoprotein and membrane, usually stimulated by alpha-interferon.
References
- ↑ Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982). "The 1982 revised criteria for the classification of systemic lupus erythematosus". Arthritis Rheum. 25 (11): 1271–7. PMID 7138600.
- ↑ Hochberg MC (1997). "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus". Arthritis Rheum. 40 (9): 1725. doi:10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y. PMID 9324032.
- ↑ Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G, Magder LS (2012). "Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus". Arthritis Rheum. 64 (8): 2677–86. doi:10.1002/art.34473. PMC 3409311. PMID 22553077.
- ↑ Lee LC, Lam KK, Lee CT, Chen JB, Tsai TH, Huang SC (2007). ""Full house" proliferative glomerulonephritis: an unreported presentation of subacute infective endocarditis". J. Nephrol. 20 (6): 745–9. PMID 18046678.
- ↑ Haas M, Kaul S, Eustace JA (April 2005). "HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases". Kidney Int. 67 (4): 1381–90. doi:10.1111/j.1523-1755.2005.00215.x. PMID 15780090.
- ↑ Ramos-Casals M, Font J, García-Carrasco M, Cervera R, Jiménez S, Trejo O, de la Red G, Sánchez-Tapias JM, Ingelmo M (December 2000). "Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus". Arthritis Rheum. 43 (12): 2801–6. doi:10.1002/1529-0131(200012)43:12<2801::AID-ANR21>3.0.CO;2-V. PMID 11145039.
- ↑ Smet AD, Kuypers D, Evenepoel P, Maes B, Messiaen T, Van Damme B, Vanrenterghem Y (November 2001). "'Full house' positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt". Nephrol. Dial. Transplant. 16 (11): 2258–62. PMID 11682680.
- ↑ Rich SA (January 1995). "De novo synthesis and secretion of a 36-kD protein by cells that form lupus inclusions in response to alpha-interferon". J. Clin. Invest. 95 (1): 219–26. doi:10.1172/JCI117643. PMC 295410. PMID 7814619.